Neurocrine Biosciences (NBIX) said late Thursday the US Food and Drug Administration granted an orphan drug designation to valbenazine for the potential...
Richard F Pops, Director, on May 09, 2022, sold 15,000 shares in Neurocrine Biosciences (NBIX) for $1,144,463. Following the Form 4 filing with the SEC,...
Expected Earnings Release: 05/04/2022, After-hours Avg. Extended-Hours Dollar Volume: $11,976,203 Neurocrine Biosciences (NBIX) is due to issue its...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 12780 El Camino Real San Diego, California 92130 |
| Phone | +1.858.617.7600 |
| Number of Employees | 585 |
| Recent SEC Filing | 05/11/2022 4 |
| Chief Executive Officer & Director | Kevin Charles Gorman |
| Vice President-Information Technology & Operations | Bill Wilson |
| Chief Financial Officer | Matthew C. Abernethy |
| Chief Research Officer | Dimitri E. Grigoriadis |
| Price Open | $83.32 |
| Previous Close | $84.12 |
| 52 Week Range | $71.88 - 108.02 |
| Market Capitalization | $8.1 B |
| Shares Outstanding | 95.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 116.83 |
| Earnings per Share | $1.21 |
| Beta vs. S&P 500 | N/A |
| Revenue | $451.2 M |
| Net Profit Margin | 5.91% |
| Return on Equity | 5.30% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
